Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
23 November 2021
Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio. Sanifit, based in Palma (Spain) has had the backing of international and Spanish funds, among which are the CataloniaBio & HealthTech members Alta Life Sciences, Ysios Capital and Healthequity, as well as Caixa Capital Risc, Columbus Venture Partners, and Innvierte from CDTI.
Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company’s portfolio of ...